Chang Hong, Ning Yi, Qi Xiaoying, Yeung Joanna, Xu Wei
Department of Laboratory Hematology, University Health Network, University of Toronto, Toronto, ON, Canada.
Br J Haematol. 2007 Oct;139(1):51-4. doi: 10.1111/j.1365-2141.2007.06750.x.
The combination of fluorescence in situ hybridization with cytoplasmic light chain detection identified chromosome 1p21 deletion in 18 (20%) of 87 patients with multiple myeloma. 1p21 deletion was associated with higher serum calcium level, 13q deletion, and t(4;14). Patients with 1p21 deletions had a significantly shorter progression-free survival (PFS) (median 10.5 vs. 22.3 months, P = 0.0002) and shorter overall survival (OS) (median 33.9 months vs. not reached, P = 0.002) than those without 1p21 deletions. On multivariate analysis, which included deletions of 13q, TP53, t(4;14) and CKS1B amplification, 1p21 deletion remained as an independent risk factor for PFS (P = 0.01) and OS (P = 0.04).
荧光原位杂交与细胞质轻链检测相结合，在87例多发性骨髓瘤患者中的18例（20%）中检测到1号染色体1p21缺失。1p21缺失与较高的血清钙水平、13号染色体长臂缺失和t(4;14)相关。与无1p21缺失的患者相比，有1p21缺失的患者无进展生存期（PFS）显著缩短（中位值分别为10.5个月和22.3个月，P = 0.0002），总生存期（OS）也较短（中位值分别为33.9个月和未达到，P = 0.002）。在多变量分析中，纳入了13号染色体长臂缺失、TP53、t(4;14)和CKS1B扩增，1p21缺失仍然是PFS（P = 0.01）和OS（P = 0.04）的独立危险因素。
